肽基检查点免疫调节剂LD01减轻小鼠多微生物脓毒症免疫功能障碍
研究用盲肠结扎穿刺(CLP)诱导的小鼠多微生物脓毒症模型,评估肽基PD-1检查点拮抗剂LD01对生存、细菌清除和宿主免疫的影响。LD01治疗显著提高生存率并降低细菌负荷,生存改善与巨噬细胞吞噬活性增强及T细胞产生干扰素-γ增加相关。LD01组髓过氧化物酶水平和酯酶阳性细胞显著减少。作者认为LD01调节宿主免疫,是减轻脓毒症免疫抑制的可行候选治疗药物。
要点
- 在CLP诱导的小鼠多微生物脓毒症模型中,LD01治疗显著提高生存率并降低细菌负荷。
- LD01组生存改善与巨噬细胞吞噬活性增强及T细胞干扰素-γ产生增加相关。
- LD01组髓过氧化物酶水平和酯酶阳性细胞显著减少。
- 肽基药物具有快速药代动力学特征,可能减少持续性PD-1通路阻断所致免疫相关不良事件。
- 作者认为LD01调节宿主免疫,是减轻脓毒症及其他感染性疾病免疫抑制的可行候选治疗药物。
适用人群与场景
- 盲肠结扎穿刺(CLP)诱导的小鼠多微生物脓毒症模型。
处置流程与药物剂量
- LD01为肽基PD-1检查点拮抗剂,本研究在小鼠CLP脓毒症模型中给予LD01治疗;原文未写明剂量、给药途径、频次或疗程。
研究设计与关键结果
- 研究类型为动物实验(小鼠CLP脓毒症模型),评估LD01对生存、细菌清除和宿主免疫的影响。
- LD01治疗显著提高CLP脓毒症小鼠生存率并降低细菌负荷。
- 生存改善与巨噬细胞吞噬活性增强及T细胞干扰素-γ产生增加相关。
- LD01组髓过氧化物酶水平和酯酶阳性细胞显著减少。
证据类型、等级与局限
- 证据类型为动物实验(小鼠CLP脓毒症模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为LD01调节宿主免疫,是减轻脓毒症及其他感染性疾病免疫抑制的可行候选治疗药物。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Sepsis-induced immunosuppression involves both innate and adaptive immunity and is associated with the increased expression of checkpoint inhibitors, such as programmed cell-death protein 1 (PD-1). The expression of PD-1 is associated with poor outcomes in septic patients, and in models of sepsis, blocking PD-1 or its ligands with antibodies increased survival and alleviated immune suppression. While inhibitory antibodies are effective, they can lead to immune-related adverse events (irAEs), in part due to continual blockade of the PD-1 pathway, resulting in hyperactivation of the immune response. Peptide-based therapeutics are an alternative drug modality that provide a rapid pharmacokinetic profile, reducing the incidence of precipitating irAEs. We recently reported that the potent, peptide-based PD-1 checkpoint antagonist, LD01, improves T-cell responses. The goal of the current study was to determine whether LD01 treatment improved survival, bacterial clearance, and host immunity in the cecal-ligation and puncture (CLP)-induced murine polymicrobial sepsis model. LD01 treatment of CLP-induced sepsis significantly enhanced survival and decreased bacterial burden. Altered survival was associated with improved macrophage phagocytic activity and T-cell production of interferon-γ. Further, myeloperoxidase levels and esterase-positive cells were significantly reduced in LD01-treated mice. Taken together, these data establish that LD01 modulates host immunity and is a viable therapeutic candidate for alleviating immunosuppression that characterizes sepsis and other infectious diseases.
参考来源
- Phares TW, Kotraiah V, Chung CS, et al. A Peptide-Based Checkpoint Immunomodulator Alleviates Immune Dysfunction in Murine Polymicrobial Sepsis. Shock. 2021. PMID: 33065715. doi:10.1097/SHK.0000000000001682
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。